Search Results - "Molin, Graziela Zibetti Dal"

Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors by Zibetti Dal Molin, Graziela, Westin, Shannon Neville, Msaouel, Pavlos, Gomes, Larissa M, Dickens, Andrea, Coleman, Robert L

“…To describe discrepancies in calculated and measured glomerular filtration rate in patients using PARP (poly ADP ribose polymerase) inhibitors who had an…”
Get more information

First report of hepatic hematoma after presumed Bothrops envenomation by Cunha, Fernanda Cristina, Heerdt, Maike, Torrez, Pasesa Pascuala Quispe, França, Francisco Oscar de Siqueira, Molin, Graziela Zibetti Dal, Battisti, Rúbia, Zannin, Marlene

“…In Latin America, Bothrops envenomation is responsible for the majority of accidents caused by venomous snakes. Patients usually present local edema, bleeding…”
Get full text

Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial by Coleman, Robert L., Handley, Katelyn F., Burger, Robert, Molin, Graziela Zibetti Dal, Stagg, Robert, Sood, Anil K., Moore, Kathleen N.

“…To evaluate the safety and preliminary efficacy of demcizumab (DLL4 targeted IgG2 humanized monoclonal antibody; potent inhibitor of the Notch pathway) in…”
Get full text

A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer by Chelariu-Raicu, Anca, Nick, Alpa, Urban, Renata, Gordinier, Mary, Leuschner, Carola, Bavisotto, Linda, Molin, Graziela Zibetti Dal, Whisnant, John K., Coleman, Robert L.

“…This randomized open-label phase II study evaluated the safety and clinical activity of EP-100 plus weekly paclitaxel in patients with recurrent ovarian cancer…”
Get full text

Recommendations for the prevention, screening, diagnosis, staging, and management of cervical cancer in areas with limited resources: Report from the International Gynecological Cancer Society consensus meeting by Maluf, Fernando Cotait, Dal Molin, Graziela Zibetti, de Melo, Andreia Cristina, Paulino, Eduardo, Racy, Douglas, Ferrigno, Robson, Uson Junior, Pedro Luiz Serrano, Ribeiro, Reitan, Moretti, Renato, Sadalla, Jose Carlos, Nogueira-Rodrigues, Angelica, Carvalho, Filomena Marino, Baiocchi, Glauco, Callegaro-Filho, Donato, Abu-Rustum, Nadeem R.

“…IntroductionNearly 85% of cervical cancer new cases are diagnosed in limited resources countries. Although several strategies have been proposed to reduce the…”
Get full text

Recommendations for the treatment of vulvar cancer in settings with limited resources: Report from the International Gynecological Cancer Society consensus meeting by Maluf, Fernando Cotait, Zibetti, Graziela Dal Molin, Paulino, Eduardo, de Melo, Andreia Cristina, Racy, Douglas, Ferrigno, Robson, Uson Junior, Pedro Luiz Serrano, Ribeiro, Reitan, Moretti, Renato, Sadalla, Jose Carlos, Nogueira Rodrigues, Angelica, Carvalho, Filomena Marino, Baiocchi, Glauco, Callegaro-Filho, Donato, Angioli, Roberto

“…IntroductionDue to scant literature and the absence of high-level evidence, the treatment of vulvar cancer is even more challenging in countries facing limited…”
Get full text

Molecular Analysis of Short- versus Long-Term Survivors of High-Grade Serous Ovarian Carcinoma by Stur, Elaine, Bayraktar, Emine, Dal Molin, Graziela Zibetti, Wu, Sherry Y, Mangala, Lingegowda S, Yao, Hui, Wang, Ying, Ram, Prahlad T, Corvigno, Sara, Chen, Hu, Liang, Han, Tworoger, Shelley S, Levine, Douglas A, Lutgendorf, Susan K, Liu, Jinsong, Moore, Kathleen N, Baggerly, Keith A, Karlan, Beth Y, Sood, Anil K

“…Despite having similar histologic features, patients with high-grade serous ovarian carcinoma (HGSC) often experience highly variable outcomes. The underlying…”
Get full text

Mutational Portrait of Lung Adenocarcinoma in Brazilian Patients: Past, Present, and Future of Molecular Profiling in the Clinic by Freitas, Helano C., Torrezan, Giovana Tardin, Cunha, Isabela Werneck da, Macedo, Mariana Petaccia, Karen de Sá, Vanessa, Corassa, Marcelo, Ferreira, Elisa Napolitano e, Saito, Augusto Obuti, Dal Molin, Graziela Zibetti, Cordeiro de Lima, Vladmir C., Carraro, Dirce Maria

“…Objectives: Approximately 60% of lung adenocarcinomas (LAs) carry mutations that can guide treatment with tyrosine-kinase inhibitors (TKI) and other targeted…”
Get full text

Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma by Zibetti Dal Molin, Graziela, Abrahão, Carina Meira, Coleman, Robert L, Maluf, Fernando Cotait

“…Ovarian carcinosarcoma is a rare malignancy associated with a high rate of cancer-related mortality even at early stages. Guidelines for systemic treatment…”
Get full text

Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study by Pant, Shubham, Schuler, Martin, Iyer, Gopa, Witt, Olaf, Doi, Toshihiko, Qin, Shukui, Tabernero, Josep, Lugowska, Iwona, Carranza, Omar, Arnold, Dirk, Gutierrez, Martin, Winter, Helen, Stuyckens, Kim, Crow, Lauren, Najmi, Saltanat, Thomas, Shibu, Santiago-Walker, Ademi, Triantos, Spyros, Sweiti, Hussein, Loriot, Yohann, Carranza, Omar, Coward, Jim, Joshua, Anthony, Karapetis, Christos, Hart, Christopher, Zhang, Alison, Prenen, Hans, Goeminne, Jean-Charles, Machiels, Jean-Pascal, Rottey, Sylvie, Corassa, Marcelo, Molin, Graziela Zibetti Dal, Tiscoski, Katsuki, Mak, Milena, Fu, Wei, Yao, Herui, Jiang, Haiping, Qin, Shukui, Chen, Baoshi, Yang, Yu, Loriot, Yohann, Le Tourneau, Christophe, Penel, Nicolas, Durando, Xavier, Emambux, Sheik, Folprecht, Gunnar, Arnold, Dirk, Schuler, Martin, Ahrens, Marit, Golf, Alexander, Haag, Georg Martin, Desuki, Alexander, Cazzaniga, Marina, Ciardiello, Fortunato, Koyama, Takafumi, Aogi, Kenjiro, Kuboki, Yasutoshi, Lee, Jungyun, Kim, Sung-Bae, Chang, Jong Hee, Kim, Yong-Man, Nam, Do-Hyun, Park, Jae-Sung, Lugowska, Iwona, Paz-Ares, Luis, Moreno, Victor, Calvo, Mariona, Falcon, Alejandro, Gonzalez, Antonio, Tabernero, Josep, Martinez Bueno, Alejandro, García-Corbacho, Javier, Chen, Jen-Shi, Hou, Ming-Feng, Chao, Yee, Rau, Kun-Ming, Chiu, Tai-Jan, Feng, Yin-Hsun, Hsu, Chih-Hung, Lai, Kuan-Ming, Yeh, Su-peng, Minchom, Anna, Welsh, Liam, Plummer, Ruth, Gutierrez, Martin, Arrowsmith, Edward, Pant, Shubham, Spigel, David Robert, Zandberg, Dan Paul, Doroshow, Deborah, Moezi, Mehdi, Paulson, Scott, Reardon, David, Ward, Patrick, Chaves, Jorge, Hussein, Atif, Manda, Sudhir, Richey, Stephen L, Tamura, David, Wilks, Sharon

“…FGFR alterations are reported across various malignancies and might act as oncogenic drivers in multiple histologies. Erdafitinib is an oral, selective…”
Get full text

Frailty repels the knife: the impact of frailty index on surgical intervention and outcomes by Handley, Katelyn, Sood, Anil, Dal Molin, Graziela Zibetti, Westin, Shannon, Meyer, Larissa, Fellman, Bryan, Soliman, Pamela, Fleming, Nicole

“…We aimed to assess the impact of frailty in ovarian cancer patients on surgical procedures and outcomes. A retrospective review of a prospectively collected…”
Get full text

A phase II trial of palbociclib combined to letrozole after progression on second-line chemotherapy for women with ER/PR-positive high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer: LACOG 1018 by Damian, Fernanda Bronzon, Melo, Andreia Cristina De, Zibetti Dal Molin, Graziela, Rodrigues, Angelica Nogueira, Calabrich, Aknar Freire de Carvalho, Werutsky, Gustavo, Filho, Elias Abdo, Rebelatto, Taiane Francieli, de Jesus, Rafaela Gomes, Jimenez, Mirela Foresti

“…5514 Background: Treatment options for patients with high-grade ovarian serous (HGSC) or endometrioid carcinoma (HGEC) who progress after receiving…”
Get full text

Can HIPEC be used against platinum-resistance and for inducing sensitivity to PARP inhibitors in ovarian cancer? by Batista, Thales Paulo, Dal Molin, Graziela Zibetti

“…Hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as a main comprehensive treatment of epithelial ovarian cancer (EOC). Despite much criticism to…”
Get full text

Efficacy and safety of erdafitinib in adults with NSCLC and prespecified fibroblast growth factor receptor alterations in the phase 2 open-label, single-arm RAGNAR trial by Schuler, Martin H., Tabernero, Josep, Carranza, Omar, Loriot, Yohann, Pant, Shubham, Arnold, Dirk, Folprecht, Gunnar, Palmer, Daniel H., Prenen, Hans, Zibetti Dal Molin, Graziela, Lugowska, Iwona A., Cervantes, Andres, Sweiti, Hussein, Hammond, Constance, Najmi, Saltanat, Thomas, Shibu, Triantos, Spyros, Xia, Karen, Gutierrez, Martin

“…8515 Background: Erdafitinib is an oral selective pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor approved in the US for treatment of…”
Get full text

Efficacy and safety of erdafitinib in patients with advanced or metastatic cholangiocarcinoma and FGFR alterations: Pooled analysis of RAGNAR and LUC2001 studies by Pant, Shubham, Park, Joon Oh, Su, Wu-Chou, Schuler, Martin H., Loriot, Yohann, Iyer, Gopa, Doi, Toshihiko, Qin, Shukui, Tabernero, Josep, Prenen, Hans, Folprecht, Gunnar, Winter, Helen, Zibetti Dal Molin, Graziela, Sweiti, Hussein, Najmi, Saltanat, Hammond, Constance, Liao, Huimin, Thomas, Shibu, Triantos, Spyros, Feng, Yin-Hsun

“…4121 Background: Erdafitinib is an oral selective pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor approved in the US for the treatment…”
Get full text

Frailty repels the knife: The impact of frailty index on surgical intervention and outcomes by Handley, Katelyn F., Sood, Anil K., Molin, Graziela Zibetti Dal, Westin, Shannon N., Meyer, Larissa A., Fellman, Bryan, Soliman, Pamela T., Coleman, Robert L., Fleming, Nicole D.

“…To assess the impact of frailty in patients with ovarian cancer on surgical procedures and outcomes. A retrospective review of patients with stage II-IV…”
Get full text

Abstract A26: Molecular analysis of short- vs. long-term ovarian cancer survivors by Stur, Elaine, Dal Molin, Graziela Zibetti, Wu, Sherry, Baggerly, Keith, Tworoger, Shelley, Levine, Douglas, Karlan, Beth, Moore, Kathleen, Lutgendorf, Susan, Sood, Anil

“…Background: High-grade serous ovarian carcinomas (HGSOC) comprise the majority of ovarian cancer cases and usually present at diagnosis with late stages of…”
Get full text

Efficacy and safety of erdafitinib in adults with cholangiocarcinoma (CCA) with prespecified fibroblast growth factor receptor alterations ( FGFRalt ) in the phase 2 open-label, single-arm RAGNAR trial: Expansion cohort results by Pant, Shubham, Schuler, Martin H., Iyer, Gopa, Doi, Toshihiko, Qin, Shukui, Tabernero, Josep, Arnold, Dirk, Gutierrez, Martin, Prenen, Hans, Folprecht, Gunnar, Winter, Helen, Cosman, Rasha, Zibetti Dal Molin, Graziela, Xia, Qi, Najmi, Saltanat, Hammond, Constance, Thomas, Shibu, Triantos, Spyros, Sweiti, Hussein, Loriot, Yohann

“…610 Background: Erdafitinib (erda) is an oral selective pan-FGFR tyrosine kinase inhibitor approved to treat locally advanced or metastatic urothelial…”
Get full text

First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial by Marth, Christian, Moore, Richard G., Bidziński, Mariusz, Pignata, Sandro, Ayhan, Ali, Rubio, M. Jesús, Beiner, Mario, Hall, Marcia, Vulsteke, Christof, Braicu, Elena Ioana, Sonoda, Kenzo, Wu, Xiaohua, Frentzas, Sophia, Mattar, André, Lheureux, Stephanie, Chen, Xiaojun, Hasegawa, Kosei, Magallanes-Maciel, Manuel, Choi, Chel Hun, Shalkova, Mariia, Kaen, Diego, Wang, Peng-Hui, Berger, Regina, Okpara, Chinyere E., McKenzie, Jodi, Yao, Lili, Orlowski, Robert, Khemka, Vivek, Gilbert, Lucy, Makker, Vicky, Kaen, Diego Lucas, Gomez Abuin, Gonzalo, Zamora, Liliana Beatriz, Alfie, Margarita Sonia, Casarini, Ignacio Alfredo, Harrison, Michelle, Ananda, Sumitra, Shannon, Catherine Margaret, Frentzas, Sophia, Friedlander, Michael, Meniawy, Tarek, Gao, Bo, Baron-Hay, Sally, Diakos, Connie, Marth, Christian, Polterauer, Stephan, Petru, Edgar, De Bock, Marlies, Vulsteke, Christof, Baurain, Jean-Francois, Van Gorp, Toon, Altintas, Sevilay, Lima, Joao Paulo da Silveira Nogueira, Mattar, Andre, de Freitas Junior, Ruffo, Santana, Rosane O., de Melo, Andreia Cristina, Franke, Fabio Andre, Zibetti Dal Molin, Graziela, Damian, Fernanda Bronzon, Guedes, João Daniel Cardoso, Ellard, Susan, Tinker, Anna, Samouëlian, Vanessa, Fortin, Suzanne, Bessette, Paul, Kolinsky, Michael, Kumar Tyagi, Nidhi, Ethier, Josee-Lyne, Gilbert, Lucy, Lheureux, Stephanie, MacKay, Helen, Lim, Charles, Wu, Xiaohua, Pan, Lingya, An, Ruifang, Chen, Xiaojun, Zheng, Hong, Wu, Yumei, Zhu, Jianqing, Yao, Shuzhong, Jia, Xuemei, Huang, Yi, Lv, Weiguo, Zhang, Yu, Zhou, Qi, Ma, Cailing, Chekerov, Radoslav, Mach, Pawel, Witteler, Ralf, Marmè, Frederik, Cadoo, Karen, Korach, Jacob, Levy, Talia, Beiner, Mario, Amnon, Amit, Scollo, Paolo, Naglieri, Emanuele, Pignata, Sandro, Zamagni, Claudio

Get full text

Prospective assessment of hypercalcemia of malignancy and infectious complications by Tavares, Monique Celeste, Dal Molin, Graziela Zibetti, Felismino, Tiago Cordeiro, Fanelli, Marcello Ferretti, Freitas, Helano C., Barros e Silva, Milton Jose

“…Abstract only e20644 Background: The hypercalcemia of malignancy (HM) is the major metabolic disorder seen in oncologic patients. Is a poor prognostic factor,…”
Get full text